TP53 is mutated in ~40–50% HCC cases and TP53 supplementation via AD is being evaluated in advanced HCC patients in clinical trials NCT02561546 (patients with diabetes) and NCT02509169 in combination with trans arterial embolization (TAE), in NCT02418988 in combination with TACE, and in NCT03544723 in combination with anti-programmed death 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) immunotherapy. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.